Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by TSP Capital Management Group LLC

TSP Capital Management Group LLC decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 223,343 shares of the biopharmaceutical company's stock after selling 24,477 shares during the period. Celldex Therapeutics accounts for about 1.9% of TSP Capital Management Group LLC's portfolio, making the stock its 21st largest position. TSP Capital Management Group LLC owned 0.34% of Celldex Therapeutics worth $5,644,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CLDX. AQR Capital Management LLC increased its holdings in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after acquiring an additional 1,504 shares during the period. Creative Planning bought a new stake in Celldex Therapeutics during the third quarter valued at about $504,000. Values First Advisors Inc. grew its stake in Celldex Therapeutics by 13.4% in the third quarter. Values First Advisors Inc. now owns 24,172 shares of the biopharmaceutical company's stock valued at $822,000 after purchasing an additional 2,853 shares during the last quarter. Novo Holdings A S raised its holdings in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after purchasing an additional 113,663 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its position in shares of Celldex Therapeutics by 92.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 243,795 shares of the biopharmaceutical company's stock valued at $8,287,000 after buying an additional 116,832 shares during the last quarter.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded down $0.16 during mid-day trading on Tuesday, hitting $22.54. The stock had a trading volume of 541,371 shares, compared to its average volume of 985,970. The firm has a market cap of $1.50 billion, a PE ratio of -8.77 and a beta of 1.60. The company has a 50 day moving average of $24.63 and a two-hundred day moving average of $29.62. Celldex Therapeutics, Inc. has a twelve month low of $20.91 and a twelve month high of $53.18.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CLDX shares. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $60.22.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.